- As expected, the FDA has approved GlaxoSmithKline's (NYSE:GSK) Shingrix [Zoster Vaccine (Adjuvanted)] shingles vaccine. In September, an FDA advisory committee voted 11 - 0 backing approval.
- Agenus (AGEN), the developer of the QS-21 adjuvant Stimulon used in Shingrix, is up 11% premarket on robust volume.
- Glaxo is down 0.5% premarket on robust volume.
- Previously: Agenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9% (July 10)